Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Now frankly, the 1.4% that we saw in terms of contract labor, FTEs as percentage of total FTEs in the fourth quarter was better than we had anticipated |
| Volume strength was broad-based across geographies and patient mix and exceeded our expectations |
| The fourth quarter was a strong finish to a great 2023 for our company |
| Our 2023 revenue increased 10.4% and driven by strong volume growth with total discharges up 8.7%, inclusive of same-store growth of 4.8% |
| Our strong volume growth continues to provide evidence that our value proposition is resonating with referral sources, payers and patients |
| Our 2023 adjusted EBITDA increased 18.5%, driven by revenue growth and prudent expense management |
| So, our Town acquisition team has been very successful in helping to support the hospitals as well as the new ramp-ups and finding and hiring nurses |
| The strong growth in adjusted EBITDA facilitated an adjusted free cash flow increase of 54.6% to $525.7 million |
| So, we're very pleased with the progress that we've made and are hiring of RNs and would accept this year to be another strong year with that |
| We think that those trends will bode well for us in the future just based on the quality of outcomes that we're producing and the complexity of the patients that we're able to treat effectively |
| So, it's been a huge support in terms of our ability to take the volume that Doug alluded to and to start off in these markets on the new markets on a good, solid fitting |
| So, the guidance that we're providing right now is according to the philosophy that we have consistently applied the businesses out there and if the environment is better, we'll deliver better results |
| So, it was very broad-based in terms of our overall growth, and we're confident that we're building a good foundation |
| So again, we think there continues to be significant upside in Medicare Advantage for us |
| We continue to see improvement in year-over-year premium labor costs |
| I would call out stroke because we think we have a particular strong outcome |
| We -- again, across all of the metrics that we've cited, we're seeing improving labor market conditions |
| I think that going back to last two years or three years, we've proven ourselves very capable of taking a higher acuity patient and having great outcomes with them |
| Doug Coltharp And I think it's all proving to be a very good trade |
| We -- as you know, we saw a nice volume growth across all 8 of our geographic regions |
| So, I guess my question around volumes because you highlighted volumes also came in better than your internal expectations and obviously, very robust growth year-over-year |
| So, we continue to demonstrate very positive numbers there |
| Our Q4 adjusted EBITDA also benefited from favorable trends in group medical claims under our self-insured program |
| But as Mark said, we're very pleased there |
| Our strong free cash flow generation allowed us to fund these investments and shareholder distributions with internally generated funds, all while reducing our net leverage to 2.7 times at year-end 2023 from 3.4 times at the end of 2022 |
| Q4 adjusted EBITDA also increased 9.6% over the prior year as the contribution from increased volume and favorable operating expenses was partially offset by an incremental bad debt reserve |
| Doug Coltharp We believe our competitive advantage in this regard is self-perpetuating providing that we operate under a philosophy of continuous improvement |
| But we've been able to grow that while maintaining or increasing the number of those contracts that are paid on a case rate basis versus a per diem and keeping that narrowing and then keeping that payment differential versus fee-for-service at less than 5% |
| Revenue for the quarter increased 9.6% over the prior year, driven primarily by volume growth |
| As Mark stated, Q4 was a strong finish to 2023 |
| Statement |
|---|
| As I just mentioned, at no point in 2023, where we are unable to take volume because of labor constraints |
| So, it's frustrating |
| If you look back at prior year, that was a negative net |
| But just broadly, when we think about what could drive margins lower year-over-year |
| And we overperformed with regard to EBITDA and adjusted cash flow |
| At no point during 2023 did we find ourselves constrained in being able to take volume and to take it safely into the best interest of the patient because of labor constraints |
| With some specifics on turnover, our RN turnover for all of 2023 was down 500 basis points from 2022 and therapy, which has always been best of class and low from a turnover perspective, was down 130 basis points on a year-over-year basis |
| And if you think about the period of the year that's extremely difficult to hire new staff it's around the holidays and particularly in Q4 |
| As we've noted previously, we had run just below 1% pre the Q3 of 2021 when the spike occurred for the overall industry |
| But as you note, if the entire industry is performing quite well, you'd wonder why they would continue on with it |
| Persistent vigilance on premium labor utilization facilitated a 32.9% decrease in contract labor plus sign-on and shift bonuses |
| On a sequential basis, premium labor decreased by $2.7 million |
| There are a number of them that were working in full this year around dysphagia, helping the patients and they're swallowing difficulties, which is a common issue with stroke patients |
| So unfortunately, just one more question about labor |
| In other words, they've not seen it from a perspective that there was a financial mode to reduce average length of stay |
| We reduced contract labor FTEs from an average of 547 in 2022 to 425 in 2023 and contract labor FTEs as a percent of total FTEs from an average of 2.2% to 1.6% over the same period |
| Certain risks and uncertainties, like those relating to regulatory developments as well as volume, bad debt and labor cost trends that could cause actual results to differ materially from our projections, estimates and expectations are discussed in the company's SEC filings, including the earnings release and related Form 8-K, and the Form 10-K for the year ended December 31, 2023, when filed |
| Doug Coltharp Which is not in any way to express disappointment regarding any of the others |
| And some of the pressures or some of the focus that you're now seeing from CMS on the MA plan is about denial of access to care and utilizing internal metrics and algorithms to authorize care for Medicare Advantage patients, which is not necessarily directing those patients to the place where they can expect the best outcome |
| It looks like the guidance is implying about year-over-year contraction on your reported 2023 figures, maybe a little bit less than that when adjusting for the reserve, the benefits and the de novo outperformance |
Please consider a small donation if you think this website provides you with relevant information